No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world.

More than 2,000 lawsuits are now targeting the makers of Ozempic and Zepbound, with patients claiming the drugs caused dangerous and sometimes permanent health problems. The cases, consolidated in Pennsylvania

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh evidence.

The weight loss injectable Ozempic has faced several lawsuits in 2025 from people who had a negative experience with the semaglutide.

Serena Williams opens up about hitting a weight loss plateau and why she turned to Zepbound to achieve her fitness goals.

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don’t go through insurance.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those with previous adverse reactions.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.

Fact checked by Nick Blackmer With anti-obesity medications like Ozempic, Wegovy, and Zepbound exploding in popularity in recent years, there’s no shortage of chatter about surprising side effects, such as “Ozempic face” and “Ozempic butt.